Remington Davis Incorporated — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$145,854	82
2024	Research	$238,875	88
2023	Research	$98,162	27
2022	Research	$114,044	18
2021	Research	$36,300	30
2020	Research	$62,767	40
2019	Research	$266,789	61

Breakdown

Who paid Research payments · program years 2019–2025

Mitsubishi Tanabe Pharma America, Inc. $482,891 197 payments
Pfizer Inc. $379,027 145 payments
Mitsubishi Tanabe Pharma Development America, Inc. $100,873 4 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 3 Placebocontrolled Randomized Observerblinded Study to Evaluate the Efficacy Safety and Tolerability of A Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $379,027 145 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability Ofmt-7117In Adults and Adolescents With Erythropoietic Protoporphyria Or X-Linked Protoporphyria $186,407 55 payments
A Phase 3, Multicenter, Open-Label, Long-Term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (Mt-7117) in Subjects With Erythropoietic Protoporphyria (Epp) Or X-Linked Protoporphyria (XLP) $117,382 59 payments
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) $88,217 2 payments
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) $48,024 1 payment
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents With Erythropoietic Protoporphyria Or X-Linked Protoporphyria $36,063 2 payments
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) $18,737 1 payment
A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) $10,068 1 payment
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon Mt-7117 in Subjects With Erythropoietic Protoporphyria Epp Or X-Linked Protoporphyria XLP $9,840 1 payment
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability ofMT-7117in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria $4,850 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.